Literature DB >> 12566019

Combined use of frequency doubling perimetry and polarimetric measurements of retinal nerve fiber layer in glaucoma detection.

Folkert K Horn1, Nhung X Nguyen, Christian Y Mardin, Anselm G Jünemann.   

Abstract

PURPOSE: The aim of this study was to evaluate the diagnostic usefulness of the combined use of frequency-doubling technology (FDT) perimetry and polarimetry of the retinal nerve fiber layer.
DESIGN: Cross-sectional study.
METHODS: Seventy ocular hypertensive patients (normal optic disk and standard perimetry, elevated intraocular pressure [>21 mm Hg]), 59 patients with "preperimetric" open-angle glaucoma (glaucomatous optic disk atrophy, elevated intraocular pressure [>21 mm Hg], no visual field defect in standard perimetry), 105 patients with "perimetric" open-angle glaucoma (glaucomatous optic disk atrophy and clearly marked visual field defect), and 73 control subjects had FDT screening (protocol: C-20-5) and polarimetric measurements (GDx). Criteria for exclusion: optic disks larger than 4 mm(2), media opacities, patients younger than 33 years or older than 66 years. None of the subjects had earlier FDT perimetry. One eye of each patient and control subject entered the statistical evaluation. Database and statistical software were used for case-wise recalculation of all missed localized probability levels to create a FDT screening score.
RESULTS: At a predefined specificity of 94.5% in control eyes, discrimination between "perimetric" glaucoma and normal subjects is superior using the FDT perimetry (sensitivity = 84.8%) in comparison to polarimetry (sensitivity = 63.8%), whereas sensitivity is similar with both methods in "preperimetric" patients (GDx, FDT: 25.4%). In several cases, patients classified as glaucomatous by the GDx are not the same patients as identified by the FDT perimetry. Therefore, a two-dimensional discrimination analysis can increase correct positive classification. Using a linear combination of the present FDT screening score and polarimetry ("the number"), 92.4% of "perimetric" glaucoma eyes and 44.1% of "preperimetric" glaucoma eyes have been classified as glaucomatous.
CONCLUSION: Joint usage of polarimetry and FDT perimetry indicate that a combination of different techniques which can uncover different glaucoma properties, might be helpful in early glaucoma detection.

Entities:  

Mesh:

Year:  2003        PMID: 12566019     DOI: 10.1016/s0002-9394(02)01926-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  GDx VCC measurements and blue-on-yellow perimetry in ocular hypertension.

Authors:  Yisheng Zhong; Liping Chen; Yu Cheng; Fangzhi Yu
Journal:  Lasers Med Sci       Date:  2012-02-03       Impact factor: 3.161

2.  Improving glaucoma detection using spatially correspondent clusters of damage and by combining standard automated perimetry and optical coherence tomography.

Authors:  Ali S Raza; Xian Zhang; Carlos G V De Moraes; Charles A Reisman; Jeffrey M Liebmann; Robert Ritch; Donald C Hood
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

3.  Frequency doubling technique perimetry and spectral domain optical coherence tomography in patients with early glaucoma.

Authors:  F K Horn; C Y Mardin; D Bendschneider; A G Jünemann; W Adler; R P Tornow
Journal:  Eye (Lond)       Date:  2010-11-19       Impact factor: 3.775

4.  Combining Frequency Doubling Technology Perimetry and Scanning Laser Polarimetry for Glaucoma Detection.

Authors:  Jean-Claude Mwanza; Joshua L Warren; Jessica T Hochberg; Donald L Budenz; Robert T Chang; Pradeep Y Ramulu
Journal:  J Glaucoma       Date:  2015 Oct-Nov       Impact factor: 2.503

5.  Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology.

Authors:  Shan C Lin; Kuldev Singh; Henry D Jampel; Elizabeth A Hodapp; Scott D Smith; Brian A Francis; David K Dueker; Robert D Fechtner; John S Samples; Joel S Schuman; Don S Minckler
Journal:  Ophthalmology       Date:  2007-10       Impact factor: 12.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.